Harbour BioMed Reports Positive Data from Myasthenia Gravis Trial

Harbour BioMed reported positive topline results from a China Phase II trial of batoclimab in patients with myasthenia gravis (gMG), an autoimmune disease. Batoclimab is a fully human anti-FcRn mAb that blocks FcRn-IgG interactions, accelerating the degradation of autoantibodies. HBM expects the candidate will treat pathogenic IgG-mediated autoimmune diseases. HBM is a novel drug discovery/development company with operations in the US , Rotterdam and Suzhou . More details.... Stock Symbol: (HK: 02142) Share this with colleagues: // //